UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 83

Sortiert nach

Clinical Relevance of Hepatic and Renal P‐gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective

Clinical pharmacology and therapeutics, 2022-09, Vol.112 (3), p.573-592

2022

Volltextzugriff (PDF)

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis

AIDS (London), 2021-07, Vol.35 (9), p.1333-1342

2021

Volltextzugriff (PDF)

Disease‐Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium

Clinical pharmacology and therapeutics, 2018-11, Vol.104 (5), p.900-915

2018

Volltextzugriff (PDF)

Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective

Clinical pharmacology and therapeutics, 2018-11, Vol.104 (5), p.916-932

2018

Volltextzugriff (PDF)

Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design

Drug metabolism and disposition, 2015-04, Vol.43 (4), p.490-509

2015

Volltextzugriff (PDF)

Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer

Pharmaceutical research, 2012-03, Vol.29 (3), p.770-781

2012

Volltextzugriff (PDF)

An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016)

Drug metabolism and disposition, 2009-02, Vol.37 (2), p.439

2009

Volltextzugriff (PDF)

In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates

Drug metabolism and disposition, 2006-05, Vol.34 (5), p.786

2006

Volltextzugriff (PDF)

Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs

The Journal of pharmacology and experimental therapeutics, 2002-12, Vol.303 (3), p.1029

2002

Volltextzugriff (PDF)

Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine

Therapeutic Advances in Infectious Disease, 2023-01, Vol.10

2023

Volltextzugriff (PDF)

Kinetic identification of membrane transporters that assist P-glycoprotein-mediated transport of digoxin and loperamide through a confluent monolayer of MDCKII-hMDR1 cells

Drug metabolism and disposition, 2008-02, Vol.36 (2), p.452

2008

Volltextzugriff (PDF)

Predicting Volume of Distribution in Humans: Performance of In Silico Methods for a Large Set of Structurally Diverse Clinical Compounds

Drug metabolism and disposition, 2021-02, Vol.49 (2), p.169-178

2021

Volltextzugriff (PDF)

Membrane transporters in drug development

Nature reviews. Drug discovery, 2010-03, Vol.9 (3), p.215-236

2010

Volltextzugriff (PDF)

In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor

Drug metabolism and disposition, 2013-02, Vol.41 (2), p.353

2013

Volltextzugriff (PDF)

Implementation of a Human Renal Proximal Tubule on a Chip for Nephrotoxicity and Drug Interaction Studies

Journal of pharmaceutical sciences, 2021-04, Vol.110 (4), p.1601-1614

2021

Volltextzugriff (PDF)

Oral Sulfasalazine as a Clinical BCRP Probe Substrate: Pharmacokinetic Effects of Genetic Variation (C421A) and Pantoprazole Coadministration

Journal of pharmaceutical sciences, 2010-02, Vol.99 (2), p.1046-1062

2010

Volltextzugriff (PDF)

Understanding the transport properties of metabolites: case studies and considerations for drug development

Drug metabolism and disposition, 2014-04, Vol.42 (4), p.650

2014

Volltextzugriff (PDF)

Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long‐acting cabotegravir and rilpivirine in clinical trials

HIV medicine, 2023-05, Vol.24 (5), p.568-579

2023

Volltextzugriff (PDF)

Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor

Pharmaceutical research, 1999-08, Vol.16 (8), p.1206-1212

1999

Volltextzugriff (PDF)

Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors

Drug metabolism and disposition, 2001-05, Vol.29 (5), p.754

2001

Volltextzugriff (PDF)

Mechanistic Basis of Cabotegravir-Glucuronide Disposition in Humans

The Journal of pharmacology and experimental therapeutics, 2019-08, Vol.370 (2), p.269

2019

Volltextzugriff (PDF)

Exact kinetic analysis of passive transport across a polarized confluent MDCK cell monolayer modeled as a single barrier

Journal of pharmaceutical sciences, 2004-08, Vol.93 (8), p.2108-2123

2004

Volltextzugriff (PDF)

Central Nervous System Disposition and Metabolism of Fosdevirine (GSK2248761), a Non-Nucleoside Reverse Transcriptase Inhibitor: An LC-MS and Matrix-Assisted Laser Desorption/Ionization Imaging MS Investigation into Central Nervous System Toxicity

Chemical research in toxicology, 2013-02, Vol.26 (2), p.241-251

2013

Volltextzugriff (PDF)

Asian participants' experience in phase 3/3b studies of long‐acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96

HIV medicine, 2024-03, Vol.25 (3), p.381-390

2024

Volltextzugriff (PDF)

1 – 25 von 83

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(80)
Mit Volltextzugriff
(59)

Publikationsform

Artikel
(82)
Buchkapitel
(1)

Sprache

Englisch
(83)
Japanisch
(16)

Erscheinungsjahr

n.n

Thema

Science & Technology
(62)
Life Sciences & Biomedicine
(60)
Pharmacology & Pharmacy
(43)
Animals
(39)
Humans
(35)
Male
(23)
Biological And Medical Sciences
(22)
Medical Sciences
(15)
Pharmacokinetics
(15)
Pharmacology. Drug Treatments
(15)
Dogs
(14)
Drug Interactions
(14)
Rats
(14)
Cell Line
(13)
Female
(13)
Atp-Binding Cassette, Sub-Family B, Member 1 - Metabolism
(11)
Chemistry
(11)
Chemistry, Multidisciplinary
(11)
Physical Sciences
(11)
Brain - Metabolism
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical Relevance of Hepatic and Renal P‐gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis

Disease‐Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium

Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective

Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design

Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer

An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016)

In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates

Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs

Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine

Kinetic identification of membrane transporters that assist P-glycoprotein-mediated transport of digoxin and loperamide through a confluent monolayer of MDCKII-hMDR1 cells

Predicting Volume of Distribution in Humans: Performance of In Silico Methods for a Large Set of Structurally Diverse Clinical Compounds

Membrane transporters in drug development

In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor

Implementation of a Human Renal Proximal Tubule on a Chip for Nephrotoxicity and Drug Interaction Studies

Oral Sulfasalazine as a Clinical BCRP Probe Substrate: Pharmacokinetic Effects of Genetic Variation (C421A) and Pantoprazole Coadministration

Understanding the transport properties of metabolites: case studies and considerations for drug development

Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure

Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long‐acting cabotegravir and rilpivirine in clinical trials

Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor

Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors

Mechanistic Basis of Cabotegravir-Glucuronide Disposition in Humans

Exact kinetic analysis of passive transport across a polarized confluent MDCK cell monolayer modeled as a single barrier

Central Nervous System Disposition and Metabolism of Fosdevirine (GSK2248761), a Non-Nucleoside Reverse Transcriptase Inhibitor: An LC-MS and Matrix-Assisted Laser Desorption/Ionization Imaging MS Investigation into Central Nervous System Toxicity

Asian participants' experience in phase 3/3b studies of long‐acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96

Suchergebnisse filtern